199 related articles for article (PubMed ID: 11357949)
1. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia.
Lodi R; Hart PE; Rajagopalan B; Taylor DJ; Crilley JG; Bradley JL; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Ann Neurol; 2001 May; 49(5):590-6. PubMed ID: 11357949
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
[TBL] [Abstract][Full Text] [Related]
3. Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease.
Schapira A; Lodi R
Methods Mol Biol; 2004; 277():293-307. PubMed ID: 15201464
[TBL] [Abstract][Full Text] [Related]
4. Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia.
Bunse M; Bit-Avragim N; Riefflin A; Perrot A; Schmidt O; Kreuz FR; Dietz R; Jung WI; Osterziel KJ
Ann Neurol; 2003 Jan; 53(1):121-3. PubMed ID: 12509856
[TBL] [Abstract][Full Text] [Related]
5. Identification and sizing of GAA trinucleotide repeat expansion, investigation for D-loop variations and mitochondrial deletions in Iranian patients with Friedreich's ataxia.
Houshmand M; Panahi MS; Nafisi S; Soltanzadeh A; Alkandari FM
Mitochondrion; 2006 Apr; 6(2):82-8. PubMed ID: 16581313
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
7. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.
Ribaï P; Pousset F; Tanguy ML; Rivaud-Pechoux S; Le Ber I; Gasparini F; Charles P; Béraud AS; Schmitt M; Koenig M; Mallet A; Brice A; Dürr A
Arch Neurol; 2007 Apr; 64(4):558-64. PubMed ID: 17420319
[TBL] [Abstract][Full Text] [Related]
8. Cardiomyopathy in Friedreich's ataxia-assessment by cardiac MRI.
Meyer C; Schmid G; Görlitz S; Ernst M; Wilkens C; Wilhelms I; Kraus PH; Bauer P; Tomiuk J; Przuntek H; Mügge A; Schöls L
Mov Disord; 2007 Aug; 22(11):1615-22. PubMed ID: 17546670
[TBL] [Abstract][Full Text] [Related]
9. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits.
Puccio H; Simon D; Cossée M; Criqui-Filipe P; Tiziano F; Melki J; Hindelang C; Matyas R; Rustin P; Koenig M
Nat Genet; 2001 Feb; 27(2):181-6. PubMed ID: 11175786
[TBL] [Abstract][Full Text] [Related]
10. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
Cooper JM; Schapira AH
Mitochondrion; 2007 Jun; 7 Suppl():S127-35. PubMed ID: 17485244
[TBL] [Abstract][Full Text] [Related]
11. Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia.
Fryer MJ
Med Hypotheses; 2002 Feb; 58(2):127-32. PubMed ID: 11812188
[TBL] [Abstract][Full Text] [Related]
12. [Cardiac manifestations of Friedreich's ataxia].
Kolek M; Mrózek V; Schenk P
Cas Lek Cesk; 2004; 143(1):48-51. PubMed ID: 15061120
[TBL] [Abstract][Full Text] [Related]
13. Friedreich's ataxia: oxidative stress and cytoskeletal abnormalities.
Sparaco M; Gaeta LM; Santorelli FM; Passarelli C; Tozzi G; Bertini E; Simonati A; Scaravilli F; Taroni F; Duyckaerts C; Feleppa M; Piemonte F
J Neurol Sci; 2009 Dec; 287(1-2):111-8. PubMed ID: 19748629
[TBL] [Abstract][Full Text] [Related]
14. Friedreich ataxia: the oxidative stress paradox.
Seznec H; Simon D; Bouton C; Reutenauer L; Hertzog A; Golik P; Procaccio V; Patel M; Drapier JC; Koenig M; Puccio H
Hum Mol Genet; 2005 Feb; 14(4):463-74. PubMed ID: 15615771
[TBL] [Abstract][Full Text] [Related]
15. Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin.
Nachbauer W; Boesch S; Schneider R; Eigentler A; Wanschitz J; Poewe W; Schocke M
PLoS One; 2013; 8(7):e69229. PubMed ID: 23922695
[TBL] [Abstract][Full Text] [Related]
16. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Seznec H; Simon D; Monassier L; Criqui-Filipe P; Gansmuller A; Rustin P; Koenig M; Puccio H
Hum Mol Genet; 2004 May; 13(10):1017-24. PubMed ID: 15028670
[TBL] [Abstract][Full Text] [Related]
17. Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study.
Lodi R; Rajagopalan B; Blamire AM; Cooper JM; Davies CH; Bradley JL; Styles P; Schapira AH
Cardiovasc Res; 2001 Oct; 52(1):111-9. PubMed ID: 11557239
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
[TBL] [Abstract][Full Text] [Related]
19. Friedreich ataxia: Detection of GAA repeat expansions and frataxin point mutations.
Pandolfo M
Methods Mol Med; 2006; 126():197-216. PubMed ID: 16930014
[TBL] [Abstract][Full Text] [Related]
20. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia.
Bradley JL; Blake JC; Chamberlain S; Thomas PK; Cooper JM; Schapira AH
Hum Mol Genet; 2000 Jan; 9(2):275-82. PubMed ID: 10607838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
